Demographic characteristics of study group and control group
| Study group | Eyes (n) (patients) (M/F) | Mean age±SD (range) years (M/F | Mean duration of medication±SD (range) months |
| Group I (antiglaucoma medication with BAK) | |||
| Group 1 A timolol with BAK | 22 (12/10) | 46±15.80 (20–65)/47±7.30 (41–60) | 9.54±2.28 (7–12) |
| Group I B timolol+PG with BAK | 36 (28/8) | 19.61±45 (16–74)/49.25±7.45 (40–65) | 9.89±1.91 (6–12) |
| Group I C PG with BAK | 24 (14/10) | 54.85±11.41 (40–68)/49.2±6.97 (41–58) | 10.75±1.82 (7–13) |
| Total | 82 | 48±14.54 (16–74) | 10.05±2.02 (6–13) |
| Group II (antiglaucoma medication without BAK) | |||
| Group II A timolol without BAK | 14 (8/6) | 30.5±9.24 (22–44)/44±19.37 (19–57) | 11±1.66 (8–12) |
| Group II B timolol+PG without BAK | 13 (7/6) | 45.86±13.50 (30–63)/55.67±4.59 (50–60) | 9.46±2.47 (7–12) |
| Group II C PG without BAK | 44 (16/28) | 42.62±17.15 (14–64/43.43±14.19 (24–72) | 9.36±2.33 (7–14) |
| Total | 71 | 43.11±15.03 (14–72) | 9.67±2.31 (7–14) |
| Total study subjects | |||
| Total number of glaucoma eyes | 153 (77) | 45.76±14.86 (14–74) | 9.88±2.15 (6–14) |
| Control eyes | 30 (30) | 29.33±5.68 (21–47) | Not applicable |
BAK, benzalkonium chloride; PG, preservative group.